The Role of Vitamin K on Knee Osteoarthritis Outcomes
Recruiting now · Phase 1/Phase 2 · Has a placebo group
Conditions studied: Osteo Arthritis Knee
In brief
The appropriate form and dosing of vitamin K to benefit relevant outcomes in knee osteoarthritis (OA) are not known. In intervention studies for conditions other than knee OA (e.g., prevention of cardiovascular disease), the most commonly used forms and doses include phylloquinone (vitamin K1; 1000µg or 500µg daily) or menaquinone-7 (MK-7 or vitamin K2; 300µg daily). However, whether these doses are adequate to increase vitamin K to levels that ameliorate risk of adverse OA outcomes is not known. Furthermore, although some studies suggest enhanced bioavailability of MK-7 over vitamin K1, as well as extra-hepatic effects, whether this is relevant for an older population with knee OA is not known, The overall goal of this pilot randomized clinical trial (RCT) is to test different subtypes and doses of vitamin K supplementation in older adults with knee OA and to measure changes in relevant biochemical measures.
Key facts
- Study ID
- NCT06385275
- Run by
- Boston University
- People needed
- 55
- Starts
- 2025-06-03
- Expected to finish
- 2026-12-01
- Last updated by the study team
- 2026-07-27
Who can join
Age: 50 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Men ≥50 years old
- Women ≥60 years old
- Clinical diagnosis of knee OA by the treating rheumatologist
- English fluency
You may not qualify if…
- Anticoagulation use (including warfarin, dabigatran, rivaroxaban, apixaban)
Where it is running
- Boston Medical Center, Rheumatology Clinic — Boston, Massachusetts, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.